Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Celgene Corporation |
---|---|
Information provided by: | Celgene Corporation |
ClinicalTrials.gov Identifier: | NCT00050843 |
The primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (MDS).
Condition | Intervention | Phase |
---|---|---|
Myelodysplastic Syndromes |
Drug: thalidomide |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Study ID Numbers: | THAL-MDS-001 |
Study First Received: | December 23, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00050843 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Anti-Bacterial Agents Preleukemia Immunologic Factors Thalidomide Precancerous Conditions Hematologic Diseases |
Myelodysplastic Syndromes Anemia Bone Marrow Diseases Angiogenesis Inhibitors Immunosuppressive Agents |
Anti-Infective Agents Disease Precancerous Conditions Thalidomide Immunologic Factors Antineoplastic Agents Hematologic Diseases Growth Substances Myelodysplastic Syndromes Physiological Effects of Drugs Angiogenesis Inhibitors Immunosuppressive Agents |
Pharmacologic Actions Anti-Bacterial Agents Preleukemia Neoplasms Pathologic Processes Therapeutic Uses Syndrome Growth Inhibitors Angiogenesis Modulating Agents Bone Marrow Diseases Leprostatic Agents |